Fosphenytoin
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Fosphenytoin: From Seizure Disorders to Manic Bipolar Affective Disorder
One-Sentence Summary
Fosphenytoin is an intravenous prodrug of phenytoin from the hydantoin anticonvulsant class; detailed original indication and mechanism-of-action text are not available in the current evidence pack, and the drug is not currently marketed in India. Among 7 TxGNN-predicted indications, only Manic Bipolar Affective Disorder is backed by any literature (2 publications, including a small clinical study), so this candidate — rather than the top-scoring but evidence-free “conjunctivitis” prediction — is the focus of this evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack — fosphenytoin is a phenytoin prodrug used as an anticonvulsant, but formal indication text is unavailable (no India license record) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.18% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on known information, fosphenytoin is a prodrug that is rapidly converted to phenytoin, a voltage-gated sodium channel blocker used to suppress excessive neuronal firing in seizure disorders.
This same membrane-stabilizing, sodium-channel mechanism is shared by several established mood stabilizers (e.g., carbamazepine, valproate), which provides a mechanistic rationale for exploring phenytoin/fosphenytoin in acute mania. However, phenytoin itself is not a recognized mood stabilizer, and its clinical role in bipolar disorder remains unestablished.
Note on other predictions: TxGNN generated 7 candidate indications for fosphenytoin. The highest-scoring one (conjunctivitis, 99.36%) and four others (nephrogenic SIAD, Tourette syndrome, myositis fibrosa, idiopathic granulomatous myositis, fibromyalgia) have no supporting clinical trials or literature and were scored L5/Hold — one rationale even notes phenytoin is associated with hyponatremia/SIADH-like reactions in case reports, i.e. the opposite of the therapeutic direction needed for nephrogenic SIAD. Manic bipolar affective disorder is therefore the only candidate with any real-world evidence and is used as the primary subject of this report.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12716241 | 2003 | Cohort (open-label) | The Journal of Clinical Psychiatry | Tested intravenous high-dose fosphenytoin as a rapid acute antimanic agent, hypothesizing anticonvulsant efficacy in mania could translate to phenytoin; used specifically because fosphenytoin avoids the cardiac/local vein side effects of IV phenytoin |
| 23205958 | 2012 | Review | Epilepsia | General historical review of how phenobarbital’s chemical structure influenced subsequent antiepileptic drug design (including phenytoin); background/mechanistic context only, not disease-specific to mania |
India Market Information
Fosphenytoin currently has no registered products in India (market_status: Not marketed, total_licenses: 0). No license records are available to summarize.
Safety Considerations
- Drug Interactions: 306 total interactions on record. Notable Major-level interactions include Cimetidine and Eliglustat. Numerous Moderate-level interactions are also recorded, spanning acid-reducing agents (Famotidine, Ranitidine), corticosteroids (Hydrocortisone, Betamethasone), diabetes medications (Acarbose, Alogliptin, Canagliflozin, Chlorpropamide, Albiglutide, Dulaglutide), vitamin D analogues (Cholecalciferol, Calcifediol, Calcitriol), and Clarithromycin. Given the breadth (306 interactions), a full interaction screen against any co-administered therapy is warranted before use.
Detailed key warnings and contraindications are not available in the current evidence pack (Blocking data gap DG001 — TFDA/regulatory labeling not yet obtained); please refer to the official package insert once available.
Conclusion and Next Steps
Decision: Hold
Rationale: The only evidence-backed candidate (manic bipolar affective disorder) rests on a single small open-label IV study from 2003 with no subsequent confirmatory trials, and the drug has no current India market presence or regulatory safety documentation. The remaining six higher-scoring TxGNN predictions have zero corroborating evidence, and one (nephrogenic SIAD) is mechanistically contradicted by known phenytoin case reports.
To proceed, the following is needed:
- Resolve Blocking data gap DG001: obtain official labeling (warnings/contraindications) before any S1 safety screening
- Resolve High-priority data gap DG002: confirm detailed MOA from DrugBank/primary literature
- Full-text appraisal of PMID 12716241 (sample size, dosing, outcome measures) to judge whether it supports advancing to a controlled trial
- A prospective, controlled study of fosphenytoin/phenytoin in acute mania before any efficacy claim
- If pursued, a full 306-interaction DDI review given the drug’s broad interaction profile
- Regulatory pathway assessment, since fosphenytoin is not currently registered in India
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.